NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371

Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371

1.1 Trastuzumab emtansine is not recommended, within its marketing authorisation, for treating adults with human epidermal growth factor 2 (HER2) positive, unresectable locally advanced or metastatic breast cancer previously treated with trastuzumab and a taxane.

1.2 People currently receiving treatment initiated within the NHS with trastuzumab emtansine that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta371

Site by Devopa
© Copyright 2020 NHS. All rights reserved.